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Abstract
Tuberculosis (TB) has re-emerged over the past two decades: in industrialized countries in association with immigration, and in Africa owing
to the human immunodeﬁciency virus epidemic. Drug-resistant TB is a major threat worldwide. The variable and uncertain impact of TB
control necessitates not only better tools (diagnostics, drugs, and vaccines), but also better insights into the natural history and
epidemiology of TB. Molecular epidemiological studies over the last two decades have contributed to such insights by answering long-
standing questions, such as the proportion of cases attributable to recent transmission, risk factors for recent transmission, the occurrence
of multiple Mycobacterium tuberculosis infection, and the proportion of recurrent TB cases attributable to re-infection. M. tuberculosis lineages
have been identiﬁed and shown to be associated with geographical origin. The Beijing genotype is strongly associated with multidrug
resistance, and may have escaped from bacille Calmette–Guerin-induced immunity. DNA ﬁngerprinting has quantiﬁed the importance of
institutional transmission and laboratory cross-contamination, and has helped to focus contact investigations. Questions to be answered in
the near future with whole genome sequencing include identiﬁcation of chains of transmission within clusters of patients, more precise
quantiﬁcation of mixed infection, and transmission probabilities and rates of progression from infection to disease of various M. tuberculosis
lineages, as well as possible variations in vaccine efﬁcacy by lineage. Perhaps most importantly, dynamics in the population structure of
M. tuberculosis in response to control measures in high-prevalence areas should be better understood.
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Tuberculosis (TB) had an estimated global incidence of
approximately 8.7 million cases in 2011, and caused 1.4 million
deaths [1]. In Europe, although TB rates are declining, the
Millennium Development Goal of 50% reduction by 2015 as
compared with 1990 will not be reached [2]. In the 1980s, TB
had been in strong decline for decades in industrialized
countries, and plans were made for TB elimination in these
countries [3,4]. In the early 1990s, this optimism was shown to
be unfounded. Drug-resistant TB emerged in New York [5],
and a molecular epidemiological study showed the importance
of ongoing transmission in that setting [6]. Moreover, it was
shown that ongoing transmission was responsible for a large
proportion of TB cases in San Francisco [7]. On a global scale,
the Global Burden of Disease Study showed that TB was
among the top ten causes of mortality and healthy life-years
lost [8,9]. In Africa, TB incidence increased steeply as a result
of the human immunodeﬁciency virus (HIV) epidemic; con-
ventional control measures were unable to control TB there
[10]. Finally, the rapid emergence of drug-resistant TB in
eastern Europe and beyond is of major concern [11,12].
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At present, the global decline in TB incidence is estimated to
be approximately 2% per year [1], despite wide adoption of the
StopTB strategy and previous predictions that thiswould lead to
a much stronger declining incidence of 5–10% per year [13,14].
In order to reach the goal of TB elimination by the year 2050, an
annual decline in the order of 15% in the incidence of TB would
be needed. The variable and uncertain impact of current TB
control measures [15,16] emphasizes the urgent need to obtain
better tools for the diagnosis, treatment and prevention of TB,
including more sensitive point-of-care diagnostics, shorter drug
regimens, and more effective vaccines. Moreover, we need to
better understand TB epidemiology in various settings. Molec-
ular tools have proven to be extremely useful in gaining a better
understanding of TB epidemiology over the past two decades.
This article summarizes the major ﬁndings and provides
suggestions for further research in the light of newopportunities
emerging today with rapid technical developments.
Molecular Typing Methods
Molecular markers for Mycobacterium tuberculosis have been
developed since the early 1990s; they reveal different levels of
genetic polymorphism, and consequently have different appli-
cations (Table 1). The technical aspects and characteristics of
the typing methodologies for M. tuberculosis complex isolates
have been described previously [17]. Spoligotyping has the
advantage of being simple and cheap, and is, to a large extent,
capable of identifying M. tuberculosis complex strains the at
(sub)species and genotype family levels [18]. Restriction
fragment length polymorphism (RFLP) typing with IS6110 as
a marker has a higher resolution than spoligotyping. The
relatively high rate of change of IS6110 banding patterns allows
distinction between M. tuberculosis complex stains [17].
Variable-number tandem-repeat (VNTR) typing allows
strain typing as well as reasonably robust phylogenetic analysis,
and this typing method is therefore being increasingly used
[19] (Fig. 1). The resolution of VNTR typing is similar to that
of RFLP. Limitations of VNTR typing for studying the
phylogeny of M. tuberculosis are that mutations may be bi-
directional and thus may undo themselves over time, and the
possibility of convergent evolution: the same arrangement in
repeats may occur independently in genetically unrelated
strains. Methods that do not suffer from these limitations are
based on the detection of large sequence polymorphisms [20]
and single-nucleotide polymorphisms [21]. Two breakthrough
studies were that of Brosch in 2002, using the former
application [20], and that of Herschberg in 2008, using the
latter [21]. Both large deletions and single-nucleotide poly-
morphisms are extremely unlikely to occur independently in
different strains, given the low DNA sequence variation in
M. tuberculosis, and the limited — although perhaps not absent
[22] — role of horizontal gene transfer. The resolution of
DNA ﬁngerprinting was enhanced by multispacer typing, based
on sequencing several intergenic regions, which were selected
on the basis of complete genome sequence analysis [23].
Whole genome sequencing (WGS) is considered to be the
maximum-resolution typing method [24–26]. It is obvious
RFLP and VNTR typing clusters can often be subdivided with
this technique, and that it adds to the overall resolution of
typing. Whether this technique can be used as a frontline
typing technique has yet to be explored.
Molecular Epidemiological Insights from the
Last Two Decades
Recent transmission
Before 1990, it was generally believed that, in low-incidence
countries, most TB cases were attributable to endogenous
reactivation of latent infection, and only a small proportion, in
the order of 10%, would derive from recent transmission
[3,27]. On the basis of this assumption, progress towards
elimination in low-incidence countries was predicted, as this
would depend mainly on the prevalence of latent infection in
older age cohorts and the natural replacement of this high-
prevalence group by younger, less infected age cohorts [3].
Two landmark studies in the 1990s overthrew this assumption
on the basis of RFLP typing. In New York and San Francisco,
>30% of TB cases were attributed to recent infection on the
basis of clustering (different patients whose isolates had the
same RFLP pattern) [6,7].
The initial studies on DNA ﬁngerprinting raised questions
about the suitability of RFLP clustering for measuring recent
transmission. For instance, in a rural population in Arkansas, it
proved impossible to identify recent epidemiological links
between the majority of clustered cases, in particular among
the elderly [28]. On the other hand, with intensive follow-up in
The Netherlands, an epidemiological link was either demon-
strated or probable in up to 85% of clustered cases [29].
TABLE 1. Suitability of genetic markers in different applica-
tions
Typing method Transmission Phylogeny Stability
IS6110 RFLP ++++  
Spoligotyping +  ++
VNTR ++++ +++ ?
Genomic deletions  ++++ +++
SNPs  ++++ +++
RFLP, restriction fragment length polymorphism; SNP, single-nucleotide polymor-
phism; VNTR, variable-number tandem-repeat.
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There are multiple reasons for an imperfect correspon-
dence between RFLP clustering and epidemiological contact
information [30]. First, conﬁrmation of contacts is expected to
have limited sensitivity. Given the long incubation period of TB,
recent transmission has been deﬁned as transmission in the
past 2–5 years [31,32]. Epidemiological conﬁrmation of all
instances of airborne transmission over such a long period is
a priori unlikely. Second, the intensity of efforts to identify
epidemiological contact is likely to be important, and may be
limited and variable under routine conditions. Third, although
the rate of change of RFLP patterns supports its use for
studying recent transmission [33], the RFLP pattern does not
change exactly after the arbitrarily deﬁned period of recent
transmission, so some cases with identical ﬁngerprints may be
linked over longer periods, and some cases linked through
recent transmission may not have isolates with identical
ﬁngerprints. Fourth, immigrants may introduce strains with
(nearly) identical DNA ﬁngerprints, which may not reﬂect
recent transmission in the study area, but rather transmission
or common strains in the country of origin. Fifth, sampling in
time, space or at random was shown to lead to underestima-
tion of clustering [34,35]. In particular, cases in small clusters
would run the risk of being misclassiﬁed as non-clustered. This
precludes the use of clustering as an indicator of recent
transmission in studies using small sampling fractions, e.g.
national sample surveys. However, as sampling in space and
time is unavoidable, and complete DNA ﬁngerprinting results
for all eligible TB cases are rarely obtained, this also served as a
warning to interpret clustering statistics cautiously [31].
Finally, the interpretation of clustering depends on factors
such as the age distribution of TB cases (clustering may
overestimate recent transmission in the elderly and under-
estimate it in the young) and the TB trend over time [36]. In a
meta-analysis, a large variation in clustering between studies
was observed, and was indeed explained in part by study
duration, sampling fraction, occurrence of strains with low
copy numbers, and TB incidence [37].
Risk factors for TB attributable to recent transmission
Risk factors for TB attributable to recent transmission include
male sex, being a young adult, being native (vs. foreign-born),
urban residence, alcohol and drug abuse, being homeless,
being exposed in crowded settings, including prisons, and
having pulmonary tuberculosis [6,7,38–42]. HIV and multidrug-
resistant TB (MDR-TB) were found to be risk factors in some
settings, but not in others [40]. As risk factors were identiﬁed
relative to the risk of TB not attributable to recent infection,
care needs to be taken in the interpretation. For instance, the
elderly in low-incidence countries have a much higher risk of
TB attributable to remote infection than the young, so the
proportion of TB in that age group attributable to recent
infection may be expected to be smaller than among the young
[36]. However, young age is also, in absolute terms, a risk factor
for recently transmitted TB. For instance, in The Netherlands,
the vast majority of TB cases attributed to recent transmission
were found among young secondary cases resulting from
recent transmission from a young index case [43,44].
Sampling bias might affect not only the clustering proportion
but also the identiﬁcation of risk factors for clustering. A
mathematical model suggested that ORs for clustering would
be underestimated as a result of sampling bias [35]. However, a
recent study showed that this sampling bias was very limited,
unless extremely small samples were taken [45]. Risk factors
for clustering can thus be used to identify priority groups for
contact investigations and intensiﬁed case-ﬁnding [46,47].
Focusing contact investigations
With the introduction of molecular typing, it was hoped that
the technique would contribute to improving contact inves-
tigations and outbreak detection. Indeed, DNA ﬁngerprinting
FIG. 1. Principle of variable-number tandem-repeat (VNTR) typing of Mycobacterium tuberculosis. The number of tandem repeats at each examined
locus can differ, and hence the length of the PCR product generated can also differ. By determining the length of the PCR product, the number of
tandem repeats present can be deduced. As this is done for 24 loci in the genome of M. tuberculosis, the standard VNTR pattern is a numerical code
of 24 numbers.
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was shown to lead to the identiﬁcation of epidemiological links,
in particular in ‘non-traditional’ settings, including bars and
churches [48]. Moreover, unsuspected outbreaks have been
detected frequently [38,49–52]. Molecular typing may also
contribute to targeting contact investigations based on the
characteristics of the ﬁrst two cases of a cluster [46].
Conversely, RFLP typing has been used to identify some of
the limitations of conventional contact investigations to
identify recent transmission. For instance, molecular epidemi-
ological ﬁndings suggested that contact investigations may be
inadequate to prevent disease if contact occurs outside the
household or close relatives or friends [49]. In Rotterdam,
molecular typing identiﬁed widespread transmission from
multiple sources among drug users, thus showing the limita-
tions of contact investigation in his high-risk population
without molecular typing, and leading to an active case-ﬁnding
programme [47,53]. In various settings, a substantial propor-
tion of household contacts were infected with a different strain
than the index case: 30% in California [54], and 54% in Cape
Town [55]; before molecular typing became available, this
would have been attributed to transmission within the
household. It is expected that replacing RFLP typing with
the much faster VNTR typing method will further help in the
targeting of contact investigations.
Nosocomial transmission
Among the ﬁrst applications of RFLP typing was the identiﬁ-
cation of outbreaks of TB among hospitalized HIV-infected
patients [56,57]. Recognition of this risk has led to the
inclusion of infection control as one of the ‘three I’s’ for the
control of TB among HIV-infected patients, the other two
being intensiﬁed TB case-ﬁnding among HIV-infected patients
and isoniazid preventive therapy.
Wereas nosocomial transmission of M. tuberculosis and
Mycobacterium bovis is hazardous for HIV-infected patients
[58], the risk to non-HIV-infected health workers and patients
appears to be variable [59,60], perhaps depending on differ-
ences between settings in patient populations and infection
control practices. The risk of nosocomial transmission was
highlighted by molecular epidemiological studies, but other
approaches have also made an important contribution to this
knowledge. In particular, an in vivo air-sampling model with
exposure of guinea pigs demonstrated the high variability in
infectiousness between patients [61,62] and the impact of
various control measures [63].
Laboratory cross-contamination
False-positive cultures as a result of laboratory cross-
contamination were demonstrated early on in the application
of DNA ﬁngerprinting [64]. Positive cultures attributed to
laboratory cross-contamination were reported to contribute
up to 3% of culture-positive cases [59,65]. Changing from the
relatively slow RFLP typing to the much faster VNTR typing
should help in the early identiﬁcation of laboratory cross
contamination [66]. This is important, as laboratory cross-
contamination may lead to false or delayed diagnosis and
unnecessary health risks and costs associated with treatment
and hospital admission [67].
Recurrent TB
Before the advent of molecular tools, the risk of re-infection
after curative treatment of TB was unclear. Quantifying this
phenomenon is important for various reasons, including a
better understanding of the role of acquired protective
immunity and hence the prospects for more effective vaccines.
Styblo suggested that the decline in incidence of TB among the
elderly in The Netherlands over the course of the 20th
century was attributable to a declining risk of TB caused by re-
infection [14]. Given the high annual risk of tuberculous
infection at the beginning of the 20th century (>10% before
1910), the prevalence of latent infection was extremely high in
these birth cohorts from adulthood onwards. The decreasing
TB incidence in these birth cohorts over the years might be
explained by a declining rate of disease attributable to re-
infection. However, other authors did not consider re-
infection to be important [68,69], and an alternative hypothesis
might explain the declining TB rates among the elderly as well,
as rates of reactivation from latent infection to disease might
have declined over time, e.g. as a result of better nutrition.
That reactivation rates vary strongly between settings was
shown by a study from Hong Kong, which estimated that the
rate of reactivation among elderly men was approxumately 17
times higher in Hong Kong than in the UK [70].
A landmark study from Cape Town provided direct
evidence of the importance of re-infection as a cause of
recurrent TB after curative treatment [71]. Among 16 patients
with recurrent TB, 12 (75%) had a strain with a different RFLP
pattern from that during the ﬁrst episode, suggesting an
extremely important role for re-infection in recurrent TB in a
high-incidence setting. In this study, HIV results were not
available, but the HIV prevalence was believed to be low. In
studies measuring HIV status, recurrent TB resulting from re-
infection was particularly common among HIV-infected
patients [72,73]. The risk among HIV-infected patients was
lowered by antiretroviral therapy [74]. A study on recurrent
TB among HIV-infected children showed that recurrence was
common, affecting 10% of children, and was attributable to
both relapse and re-infection [75]. In low-incidence settings,
on the other hand, recurrent TB was much less common, and
was rarely attributable to re-infection [76].
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A later study from Cape Town suggested that some
individuals may be particularly susceptible to TB, as the
incidence of recurrent TB attributed to re-infection was higher
than the incidence of a ﬁrst episode of TB in the same
population [77]. This ﬁnding has since been conﬁrmed
elsewhere, both for HIV-infected and for HIV-uninfected
individuals [78,79].
Although recurrent TB resulting from re-infection may have
limited relevance to TB control activities [80], it calls into
question the role of protective immunity [81]. Further
immunological studies are needed to determine the role of
protective immunity in TB and the implications for vaccine
development [82].
Multiple infection
In the early studies, RFLP patterns were generally interpreted
as being derived from one strain, as, almost invariably, the
intensities of all bands were equal, and mixtures of different
bacterial populations reﬂected in two subsets of bands with
different intensities were hardly observed. This was remark-
able, because, in the 1990s, a signiﬁcant proportion of TB
patients in western countries already came from high-preva-
lence areas, where the probability of multiple infection may be
considerable. In The Netherlands, where DNA ﬁngerprinting
has been conducted since 1993, the only indication of two
mixed RFLP patterns with different intensities was traced back
to long-term laboratory cross-contamination in a peripheral
laboratory [83]. A systematic search for RFLP patterns with
single ‘vague’ (low-intensity) bands suggested that mixed
infection might indeed occur [84]. However, in RFLP analysis
of single colonies from such isolates, the vague bands
disappeared, and bacteria of individual colonies either had a
normal-intensity band at the position of the vague band in the
parental strains, or no band at all. Therefore, transpositions of
IS6110 in the genome of M. tuberculosis, and thus genetic drift
in a part of the bacterial population, was a likely explanation. In
purposely composed mixtures of strains with different RFLP
patterns, it became clear that the limit for detection of a
second strain was approximately 10% ‘foreign’ DNA [84].
Similarly, mixtures of drug-resistant and susceptible strains
have been recognized [85].
Mixed infection with different stains has also been identiﬁed
with molecular techniques. Whereas, in low-incidence coun-
tries, the probability of multiple infection is expected to be
low, in high-incidence countries this risk may be high. For
instance, if the annual risk of infection were 4%, as has been
observed in Cape Town, South Africa [86], it can be calculated
that, at age 35 years, 24% of individuals would have escaped
infection, 35% would have been infected once, and 41% would
have been infected more than once, unless prior infection
protected against re-infection. Evidence of multiple strains
involved in TB disease has emerged in recent years. Of TB
patients in Cape Town, 19% were infected with both a Beijing
strain and a non-Beijing strain [87]. Two studies in Taiwan
found that, among TB patients, 3% and 11%, respectively, were
infected with a Beijing strain and a non-Beijing strain [88,89]. In
Malawi, 3% of patients were infected with strains of the LAM
and non-LAM lineages [90]. This suggests that multiple
infections are rather common among TB patients in high-
prevalence settings. Owing to methodological limitations
(multiple infection is demonstrated with genotype-speciﬁc
PCR testing), the extent of multiple infection contributing to
disease is likely to have been underestimated in studies thus
far. On the other hand, given the risk of contamination in PCR,
one could also argue that the problem of mixed infections is
overestimated. Therefore, more research is needed to better
clarify this important issue. Both recurrent TB after re-
infection and multiple infections call into question the role of
protective adaptive immunity and the possibilities of develop-
ing effective vaccines [81,82].
Incubation period
It has been known for a long time that the incubation period of
TB may range from a few months to many years [91,92]. The
measurement of this was challenging, because determining the
moment of infection is difﬁcult, and a long follow-up is
required, with a low risk per person necessitating large
cohorts, and re-infection may occur during follow-up.
Some decades ago, follow-up studies were performed
among contacts of infectious TB patients in the USA [91]
and in a control group of a bacille Calmette–Guerin (BCG)
vaccination trial among adolescents in the UK [92]. Among
those developing disease within 10 years, 50% did so within
2 years in the former studies and 82% in the latter. No risk
factors for short incubation periods were identiﬁed.
In a recent molecular epidemiological study in The Nether-
lands, the incubation period distribution was determined
among 1095 secondary cases attributed to 688 source cases
whose isolates had identical RFLP patterns and for whom
epidemiological contact had been reported [93]. Of those
developing TB within 15 years, 62% did so within 2 years. Risk
factors for short incubation periods were young age, male sex,
extrapulmonary TB, and not having had previous TB or
preventive therapy [93]. The latter two risk factors appear
to be consistent with some role for adaptive protective
immunity.
Drug-resistant TB
MDR-TB was an important problem during the re-emergence
of TB in New York in the early 1990s [5], and is recognized as
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a serious threat in eastern Europe and Central Asia [11,94,95].
Since 2006, extensively drug-resistant TB (XDR-TB) has been
recognized as a global problem [12,96,97], with an extremely
high mortality among HIV-positive individuals [98,99].
Recently, reports on totally drug-resistant TB have emerged
in Iran and India [100,101]. Methods to control MDR-TB are
known: ﬁrst, its emergence needs to be prevented by
appropriate treatment of drug-susceptible TB [102]; and
second, if present, MDR-TB needs to be treated adequately
to prevent transmission, death, and the development of XDR-
TB [12].
The prospects for the control of MDR-TB are unclear. An
important uncertainty is the reproductive ﬁtness of drug-
resistant strains [103,104]. One might expect drug-resistant
strains to have increased reproductive ﬁtness, as resistant
cases are likely to be infectious for a longer time than
susceptible ones, and because drug-resistant TB may occur
preferentially among certain risk groups, such as HIV-infected
individuals [105]. On the other hand, as was reported in the
1950s and 1960s, on the basis of experiments in guinea pigs,
the ﬁtness of M. tuberculosis might be impaired if underlying
mutations impact on the ability to withstand exposure to
oxygen radicals [106,107]. However, this will depend on the
speciﬁc mutations. For instance, some mutations in the katG
gene, such as the S315T mutation, will only reduce the
expression of katalase/peroxidase, whereas others will stop its
expression entirely [108]. If drug resistance-conferring muta-
tions reduce virulence, this effect may be undone through
compensatory evolution [104,109].
The incidence of drug-resistant TB has declined in some
settings [110], sometimes even in the absence of speciﬁc
control measures for drug-resistant TB [111], suggesting
reduced reproductive ﬁtness. However, this does not appear
to apply to all forms [112]. The ability to preserve ﬁtness while
becoming resistant may be associated with particular geno-
types, such as the Beijing strain [113–115]. For instance, a large
proportion of recently transmitted MDR-TB/XDR-TB strains
in the European Union are of the Beijing genotype [116,117].
RFLP clustering has been used to compare the relative
ﬁtness of drug-resistant and drug-susceptible strains. Isoniazid-
resistant strains were less likely to be clustered [38,118], but
not if resistance was attributable to the katG gene S315T
mutation [108,119]. Moreover, a wider comparison suggested
that the relative ﬁtness of drug-resistant strains varies between
settings [103]. Overall, the reproductive ﬁtness is likely to
depend both on biological factors—such as loss of virulence
and compensatory evolution—and on factors associated with
the setting—such as speed and completeness of case detec-
tion, quality of drugs and drug regimens used, and systems to
ensure treatment compliance [112].
Beijing genotype
The Beijing genotype was described in 1995 as the predom-
inant genotype in the Beijing region [120], and since then in
various Asian countries [e.g. 121]. It was initially recognized on
the basis of the characteristic IS6110 RFLP and spoligotyping
pattern; later, the deﬁnition was reﬁned [122]. Mokrousov
et al. [123] introduced the distinction between typical and
atypical Beijing strains, and this facilitated studies on the
evolutionary development of this genotype family [124,125].
For instance, it has been suggested that the success of the
more recent typical Beijing strain may be attributable to its
ability to circumvent immune protection after BCG vaccina-
tion [124].
The emergence of Beijing strains was reported in various
settings [113,115,126], e.g. in Vietnam [121], where it was
associated with young age, in the Canary Islands [127], where
an outbreak and fast spread were documented, in South Africa,
where a strong increase was seen among young children [128],
and in The Netherlands, where the incidence increased in
association with immigration and among young natives [129].
The lineage is observed all over the world, and is associated
with drug resistance in various settings [113,115,126], includ-
ing in eastern Europe, New York (where a side branch of the
Beijing lineage was known under the name ‘W’ family or W
strain [96]), and in South Africa [130].
Recently, a correlation was shown between MDR-TB and
the Beijing genotype in Colombia [131]. This may be alarming,
as these strains have hardly been found in Latin America in the
past. The strong association of the Beijing genotype with MDR-
TB/XDR-TB in eastern Europe is reﬂected in the European
Union, where the largest number of clustered patients with
MDR-TB/XDR-TB were infected with one type of Beijing
genotype strain [116,117]. Nearly half of the MDR-TB/XDR-
TB cases included in European surveillance were in clusters,
and 85% of the transmitted cases were Beijing isolates not
distinguishable with RFLP and VNTR typing. This is remark-
able, because, of the susceptible isolates in Europe, only 6–7%
are of this genotype.
Although various reasons for the emergence of the Beijing
genotype have been proposed, including escape from BCG
vaccination, an increased ability to acquire drug resistance
without loss of ﬁtness, and an increased virulence, further
research is needed [114,124]. If Beijing strains do indeed have
selective advantages over other M. tuberculosis strains and have
been emerging for a few decades, the time of divergence
should be short. On the basis of WGS of three typical and
three atypical Beijing strains from China, Vietnam, and South
Africa, the typical Beijing strains from this widespread
geographical area appeared to be genetically highly conserved,
whereas the more ancestral atypical strains were much more
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diverse [17,132] (Fig. 2). The 53 mutations that separate all
typical Beijing strains from the atypical strains were, for the
large part, traced to regulatory regions of the genome, and
may inﬂuence the overall protein expression in typical strains.
Recently, it has been found that some Beijing strains have a
much higher mutation frequency, leading to rifampicin resis-
tance [133]. Moreover, a higher dose of rifampicin was needed
to achieve 100% killing of Beijing genotype bacteria, suggesting
that Beijing bacteria have higher intrinsic resistance against this
drug [133].
Phylogeography
The ﬁrst lineage of M. tuberculosis to be found was the Beijing
genotype described in 1995 [120]. It is considered to be one of
the six main lineages distributed globally [134]. The ﬁrst
deﬁnition of Beijing strains was based on their speciﬁc
spoligotyping and IS6110 RFLP patterns [120], although both
markers have serious limitations for studying the phylogeny of
the M. tuberculosis complex. Insertion sequence IS6110 is, in
fact, a mobile genomic element that utilizes preferential
insertion sites, thus favouring convergent evolution. Never-
theless, IS6110 RFLP patterns, to a large degree, group
M. tuberculosis isolates into genotype families, and this charac-
terization is valuable for identifying, for instance, Beijing
genotype strains [122]. Spoligotyping also has been used
extensively to study the phylogeography of the M. tuberculosis
complex, and a huge database representing >39 000 isolates
from 122 countries provided the ﬁrst insights into the
distribution of genotype families worldwide [18]. Spoligotyping
offers insufﬁcient resolution in some genotype families, and
convergent evolution has been noted in offspring of well-
characterized strains [135].
Although VNTR typing was initially seen a strain typing
method, several studies have shown that the VNTR pattern is
also a valuable phylogenetic marker [136], even though
convergent evolution may occur occasionally [137].
The distribution of the six M. tuberculosis lineages appears
to differ signiﬁcantly by geographical area, with the largest
variability in Africa [134]. This is reﬂected in the names used by
Gagneux et al. (Indo-Oceanic, East Asian, East African-Indian,
Euro-American, West African lineage I, and West African
lineage II) [134]. The association between M. tuberculosis
lineages and geographical areas has been observed among
isolates from recent immigrants in low-incidence countries
[138,139], and is also emerging from many recent publications
on lineage distributions in different geographical areas. These
geographical associations are likely to be attributable, at least
in part, to historical migration patterns and perhaps the origin
of humankind, as described for Helicobacter pylori [140]. It is
interesting that Mycobacterium canettii, which is believed to be
closely linked to the common ancestor of the M. tuberculosis
complex [20,141,142], has its epicentre in the Horn of Africa,
the geographical area where humankind presumably started its
spread over the world.
There are various possible explanations for the association
between lineage and geographical area. First, the spread of
M. tuberculosis may have represented a series of population
bottlenecks (founder effect). Moreover, co-evolution between
the human host and M. tuberculosis may have played a role
[21,138]. In San Francisco, TB transmission was more common
within than between ethnic groups [138], but this association
may have been the result of social mixing rather than host–
pathogen co-evolution.
It has been shown that polymorphisms in human susceptibility
genes are associated with the clinical presentation and geno-
types ofM. tuberculosis infecting patients [143,144]. Overall, the
evidence for the role of the genotype of M. tuberculosis in
FIG. 2. Mutations in the regulatory network are associated with the
recent clonal expansion of a dominant subclone of the Mycobacterium
tuberculosis Beijing genotype. The hypothetical phylogenetic tree of the
Beijing genotype strains of M. tuberculosis is shown. The atypical Beijing
strains are genetically diverse. The typical strains presumably gained a
selective advantage over the atypical strains, and started to spread
recently. The currently isolated typical Beijing strains from a
widespread geographical area are highly clonal, which may be related
to an enhanced capacity to circumvent bacille Calmette–Guerin-
induced immunity or to withstand treatment with antituberculosis
drugs.
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transmissibility, pathogenicity and virulence in various human
populations is limited, and is more extensive for some
genotypes, such as the Beijing genotype [114], than for others.
Prospects of TB elimination and impact of immigration
In the late 1980s, TB elimination was expected to be achived
within decades in various low-incidence countries [3,4]. Since
then, progress has been slower than foreseen, owing to four
main factors: temporary neglect of TB control; the emergence
of HIV; increasing human migration; and the development of
resistance against anti-TB drugs. The impact of neglect of TB
control was most clearly observed in New York, where TB
notiﬁcation rates nearly tripled from 1978 to 1992, and then
showed a 20% decline between 1992 and 1994 after the re-
strengthening of control [110]. At around the same time, the
impact of the HIV epidemic on TB epidemiology became
evident. HIV-infected individuals have a strongly increased risk
of progressing from infection to disease [145], and HIV has led
to a strongly increased TB incidence in Africa [146]. Fortu-
nately, the HIV epidemic in industrialized countries did not
evolve into a generalized epidemic, but remained restricted to
high-risk populations. Furthermore, the risk of TB in HIV-
infected individuals was reduced after the introduction of
highly active antiretroviral therapy in the 1990s [147].
Progress towards TB elimination was slowed down by
immigration from high-incidence areas [148]. In New York,
most cases of TB among immigrants were attributed to
reactivation of latent infection [39]. In The Netherlands, a
molecular epidemiological study showed a strong decline in
the incidence of TB attributable to reactivation among the
native population, from 170 cases in 1995 to 91 cases in 2005,
more or less as predicted in 1990 [44]. The decline in the
number of index cases among foreign-born individuals was
much less (from 250 to 222 cases). The risk of transmission
from immigrants to the native population is generally low
[149–151]. However, although the absolute risk is low, the
proportion of secondary cases among the native population in
The Netherlands attributed to foreign-born index cases
increased from 29% in 1995 to 50% in 2005 [44].
Earlier studies and surveillance thus suggested that existing
control programmes should be maintained for as long as the
disease is not eliminated, that surveillance is of vital impor-
tance, and that most TB in low-incidence countries is found
among the foreign-born. Molecular epidemiological studies
have helped to quantify transmission from the foreign-born to
the native population, and can thus be used to predict progress
towards elimination. In order to accelerate progress towards
TB elimination in low-incidence countries, these countries
need to maintain programmes for TB control, use new tools as
they become available, expand the use of preventive therapy in
those with latent infection (primarily the elderly and the
foreign-born), consider expanding screening for TB infection
and disease [152], and support global TB control, as this is
expected to be most effective in the long term, and may even
be cost-effective in the short term [153].
Open Questions
Although great progress has been made in the molecular
epidemiology of TB over the last two decades, many open
questions remain.
It should be investigated whether WGS can be developed
into a practical tool to cover a large part of the laboratory
diagnosis. In principle, identiﬁcation, indicative drug suscepti-
bility testing and epidemiological typing can all be performed
with this single technique [17]. The ﬁrst studies on the value
added by WGS to current typing techniques have shown that
separate transmission chains within RFLP/VNTR typing clus-
ters can be distinguished on the basis of infrequent mutations
occurring in the offspring of bacteria [21,24,25]. For a wider
epidemiological application of this technique, it is important to
determine the rate of change of the M. tuberculosis genome.
WGS should be able to predict resistance patterns in
M. tuberculosis, although more resistance-conferring mutations
need to be identiﬁed [154]. Moreover, techniques are needed
to study mixed populations of bacteria with different resis-
tance proﬁles [155].
With wider application of DNA ﬁngerprinting, advances in
WGS, and the development of new tools for TB control and
the implementation of trials to assess these new tools, we may
be able to answer further important questions in TB control.
These include identiﬁcation of chains of transmission within
clusters of patients with identical RFLP/VNTR patterns [24]
(Fig. 3), identiﬁcation of determinants of genomic stability
[24,156], improved quantiﬁcation of mixed infection [157,158],
determination of the transmission probabilities and rates of
progression from infection to disease and clinical presentation
of various M. tuberculosis strains or lineages in various human
populations [109,159–161], identiﬁcation of correlates of
immunological protection depending on host and the M. tuber-
culosis lineage [109,134,138], improved insights into the
prospects for the control of drug-resistant TB [112], deter-
mination of the validity of new tests to diagnose latent M.
tuberculosis infection and TB dependent on lineage [134],
determination of clinical presentation and the probability of
treatment failure or relapse in association with the causative
M. tuberculosis strain [134,162,163], and the efﬁcacy of BCG
and new vaccines in relation to the causative M. tuberculosis
strains [124,134].
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But perhaps the most important research question in the
molecular epidemiology of TB concerns the dynamics in the
population structure of M. tuberculosis in high-prevalence areas
and what genetic factors underlie the ongoing selection. If the
worldwide TB epidemic is changing into an epidemic of drug-
resistant TB, the previous success in control will be reversed,
and the plague of humankind will have reinvented itself.
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